Search Results | Clinical Cancer Research | American Association for Cancer Research

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study

Daniel Morgensztern, Benjamin Besse, Laurent Greillier, Rafael Santana-Davila, Neal Ready, Christine L. Hann, Bonnie S. Glisson, Anna F. Farago, Afshin Dowlati, Charles M. Rudin, Sylvestre Le Moulec, Satwant Lally, Sreeni Yalamanchili, Jürgen Wolf, Ramaswamy Govindan, David P. Carbone

Clin Cancer Res (2019) 25 (23): 6958–6966.

DOI: https://doi.org/10.1158/1078-0432.CCR-19-1133

Published: 02 December 2019

View article

Includes: Supplementary data

Journal Articles

Adaptive Resistance to Dual BRAF/MEK Inhibition in BRAF-Driven Tumors through Autocrine FGFR Pathway Activation

Victoria E. Wang, Jenny Y. Xue, Dennie T. Frederick, Yi Cao, Eva Lin, Catherine Wilson, Anatoly Urisman, David P. Carbone, Keith T. Flaherty, Rene Bernards, Piro Lito, Jeff Settleman, Frank McCormick

Clin Cancer Res (2019) 25 (23): 7202–7217.

DOI: https://doi.org/10.1158/1078-0432.CCR-18-2779

Published: 02 December 2019

View article

Includes: Supplementary data

Journal Articles

Identification of Recurrent Activating HER2 Mutations in Primary Canine Pulmonary Adenocarcinoma

Gwendolen Lorch, Karthigayini Sivaprakasam, Victoria Zismann, Nieves Perdigones, Tania Contente-Cuomo, Alexandra Nazareno, Salvatore Facista, Shukmei Wong, Kevin Drenner, Winnie S. Liang, Joseph M. Amann, Sara L. Sinicropi-Yao, Michael J. Koenig, Krista La Perle, Timothy G. Whitsett, Muhammed Murtaza, Jeffrey M. Trent, David P. Carbone, William P.D. Hendricks

Clin Cancer Res (2019) 25 (19): 5866–5877.

DOI: https://doi.org/10.1158/1078-0432.CCR-19-1145

Published: 01 October 2019

View article

Includes: Supplementary data

Journal Articles

Abstract IA20: Immunotherapy: Biomarkers and checkpoint blockade in NSCLC

David P. Carbone, Michael Sharpnack, Kai He

Clin Cancer Res (2018) 24 (17_Supplement): IA20.

DOI: https://doi.org/10.1158/1557-3265.AACRIASLC18-IA20

Published: 01 September 2018

View article

Journal Articles

SMARCA4/BRG1 Is a Novel Prognostic Biomarker Predictive of Cisplatin-Based Chemotherapy Outcomes in Resected Non–Small Cell Lung Cancer

Erica Hlavin Bell, Arup R. Chakraborty, Xiaokui Mo, Ziyan Liu, Konstantin Shilo, Simon Kirste, Petra Stegmaier, Maureen McNulty, Niki Karachaliou, Rafael Rosell, Gerold Bepler, David P. Carbone, Arnab Chakravarti

Clin Cancer Res (2016) 22 (10): 2396–2404.

DOI: https://doi.org/10.1158/1078-0432.CCR-15-1468

Published: 12 May 2016

View article

Includes: Supplementary data

Journal Articles

Leveling the Playing Field: Bringing Development of Biomarkers and Molecular Diagnostics up to the Standards for Drug Development

George Poste, David P. Carbone, David R. Parkinson, Jaap Verweij, Stephen M. Hewitt, J. Milburn Jessup

Clin Cancer Res (2012) 18 (6): 1515–1523.

DOI: https://doi.org/10.1158/1078-0432.CCR-11-2206

Published: 14 March 2012

View article

Journal Articles

Abstract A9: Pharmacological stimulation of DLL1-Notch signaling as an antitumor immunotherapy

Yuhui Huang, Luping Lin, Asel K. Biktasova, Anshu Malhotra, Anil Shanker, David P. Carbone, Mikhail M. Dikov

Clin Cancer Res (2012) 18 (3_Supplement): A9.

DOI: https://doi.org/10.1158/1078-0432.12AACRIASLC-A9

Published: 01 February 2012

View article

Journal Articles

The Efficacy of IGF-I Receptor Monoclonal Antibody against Human Gastrointestinal Carcinomas is Independent of k-ras Mutation Status

Masanori Ii, Hua Li, Yasushi Adachi, Hiroyuki Yamamoto, Hirokazu Ohashi, Hiroaki Taniguchi, Yoshiaki Arimura, David P. Carbone, Kohzoh Imai, Yasuhisa Shinomura

Clin Cancer Res (2011) 17 (15): 5048–5059.

DOI: https://doi.org/10.1158/1078-0432.CCR-10-3131

Published: 31 July 2011

View article

Journal Articles

Integration of Molecular Profiling into the Lung Cancer Clinic

William Pao, Mark G. Kris, A. John Iafrate, Marc Ladanyi, Pasi A. Jänne, Ignacio I. Wistuba, Ryn Miake-Lye, Roy S. Herbst, David P. Carbone, Bruce E. Johnson, Thomas J. Lynch

Clin Cancer Res (2009) 15 (17): 5317–5322.

DOI: https://doi.org/10.1158/1078-0432.CCR-09-0913

Published: 31 August 2009

View article

Journal Articles

A Phase II Study of Celecoxib in Combination with Paclitaxel, Carboplatin, and Radiotherapy for Patients with Inoperable Stage IIIA/B Non–Small Cell Lung Cancer

Robert Mutter, Bo Lu, David P. Carbone, Ildiko Csiki, Luigi Moretti, David H. Johnson, Jason D. Morrow, Alan B. Sandler, Yu Shyr, Fei Ye, Hak Choy

Clin Cancer Res (2009) 15 (6): 2158–2165.

DOI: https://doi.org/10.1158/1078-0432.CCR-08-0629

Published: 16 March 2009

View article

Journal Articles

Selective Profiling of Proteins in Lung Cancer Cells from Fine-Needle Aspirates by Matrix-Assisted Laser Desorption Ionization Time-of-Flight Mass Spectrometry

Joseph M. Amann, Pierre Chaurand, Adriana Gonzalez, James A. Mobley, Pierre P. Massion, David P. Carbone, Richard M. Caprioli

Clin Cancer Res (2006) 12 (17): 5142–5150.

DOI: https://doi.org/10.1158/1078-0432.CCR-06-0264

Published: 01 September 2006

View article

Includes: Supplementary data

Journal Articles

Targeting Cyclooxygenase-2 in Recurrent Non–Small Cell Lung Cancer: A Phase II Trial of Celecoxib and Docetaxel

Ildiko Csiki, Jason D. Morrow, Alan Sandler, Yu Shyr, John Oates, Myles K. Williams, Thao Dang, David P. Carbone, David H. Johnson

Clin Cancer Res (2005) 11 (18): 6634–6640.

DOI: https://doi.org/10.1158/1078-0432.CCR-05-0436

Published: 15 September 2005

View article

Journal Articles

A Training-Testing Approach to the Molecular Classification of Resected Non-Small Cell Lung Cancer

Noboru Yamagata, Yu Shyr, Kiyoshi Yanagisawa, Mary Edgerton, Thao P. Dang, Adriana Gonzalez, Sorena Nadaf, Paul Larsen, John R. Roberts, Jonathan C. Nesbitt, Roy Jensen, Shawn Levy, Jason H. Moore, John D. Minna, David P. Carbone

Clin Cancer Res (2003) 9 (13): 4695–4704.

Published: 27 October 2003

View article

Journal Articles

A Phase I/IIA Trial of Continuous Five-Day Infusion of Squalamine Lactate (MSI-1256F) Plus Carboplatin and Paclitaxel in Patients with Advanced Non-Small Cell Lung Cancer

Roy S. Herbst, Lisa A. Hammond, David P. Carbone, Hai T. Tran, Kenneth J. Holroyd, Avinash Desai, Jon I. Williams, B. Nebiyou Bekele, Howard Hait, Victoria Allgood, Stephen Solomon, Joan H. Schiller

Clin Cancer Res (2003) 9 (11): 4108–4115.

Published: 30 September 2003

View article

Journal Articles

Weekly Irinotecan and Cisplatin in Advanced Non-Small Cell Lung Cancer: A Multicenter Phase II Study

Madan H. Jagasia, Corey J. Langer, David H. Johnson, Furhan Yunus, John S. Rodgers, Larry L. Schlabach, Alan G. Cohen, Yu Shyr, David P. Carbone, Russell F. DeVore

Clin Cancer Res (2001) 7 (1): 68–73.

Published: 01 January 2001

View article

Journal Articles

Dendritic Cells Transduced with Full-Length Wild-Type p53 Generate Antitumor Cytotoxic T Lymphocytes from Peripheral Blood of Cancer Patients

Ekaterina Yu. Nikitina, Joseph I. Clark, James van Beynen, Sunil Chada, Arvind K. Virmani, David P. Carbone, Dmitry I. Gabrilovich

Clin Cancer Res (2001) 7 (1): 127–135.

Published: 01 January 2001

View article

Journal Articles

Clinical Significance of Defective Dendritic Cell Differentiation in Cancer

Bond Almand, John R. Resser, Brian Lindman, Sorena Nadaf, Joseph I. Clark, Eugene D. Kwon, David P. Carbone, Dmitry I. Gabrilovich

Clin Cancer Res (2000) 6 (5): 1755–1766.

Published: 01 May 2000

View article

Journal Articles

Antibodies to Vascular Endothelial Growth Factor Enhance the Efficacy of Cancer Immunotherapy by Improving Endogenous Dendritic Cell Function

Dmitry I. Gabrilovich, Tadao Ishida, Sorena Nadaf, Joyce E. Ohm, David P. Carbone

Clin Cancer Res (1999) 5 (10): 2963–2970.

Published: 01 October 1999

View article

Journal Articles

A Phase I Single-Dose Trial of Gadolinium Texaphyrin (Gd-Tex), a Tumor Selective Radiation Sensitizer Detectable by Magnetic Resonance Imaging

David I. Rosenthal, Pamela Nurenberg, Carlos R. Becerra, Eugene P. Frenkel, David P. Carbone, Bert L. Lum, Richard Miller, Julie Engel, Stuart Young, Dale Miles, Markus F. Renschler

Clin Cancer Res (1999) 5 (4): 739–745.

Published: 01 April 1999

View article

NARROW

Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study

Adaptive Resistance to Dual BRAF/MEK Inhibition in BRAF-Driven Tumors through Autocrine FGFR Pathway Activation

Identification of Recurrent Activating HER2 Mutations in Primary Canine Pulmonary Adenocarcinoma

Abstract IA20: Immunotherapy: Biomarkers and checkpoint blockade in NSCLC

SMARCA4/BRG1 Is a Novel Prognostic Biomarker Predictive of Cisplatin-Based Chemotherapy Outcomes in Resected Non–Small Cell Lung Cancer

Leveling the Playing Field: Bringing Development of Biomarkers and Molecular Diagnostics up to the Standards for Drug Development

Abstract A9: Pharmacological stimulation of DLL1-Notch signaling as an antitumor immunotherapy

The Efficacy of IGF-I Receptor Monoclonal Antibody against Human Gastrointestinal Carcinomas is Independent of k-ras Mutation Status

Integration of Molecular Profiling into the Lung Cancer Clinic

A Phase II Study of Celecoxib in Combination with Paclitaxel, Carboplatin, and Radiotherapy for Patients with Inoperable Stage IIIA/B Non–Small Cell Lung Cancer

Selective Profiling of Proteins in Lung Cancer Cells from Fine-Needle Aspirates by Matrix-Assisted Laser Desorption Ionization Time-of-Flight Mass Spectrometry

Targeting Cyclooxygenase-2 in Recurrent Non–Small Cell Lung Cancer: A Phase II Trial of Celecoxib and Docetaxel

A Training-Testing Approach to the Molecular Classification of Resected Non-Small Cell Lung Cancer

A Phase I/IIA Trial of Continuous Five-Day Infusion of Squalamine Lactate (MSI-1256F) Plus Carboplatin and Paclitaxel in Patients with Advanced Non-Small Cell Lung Cancer

Weekly Irinotecan and Cisplatin in Advanced Non-Small Cell Lung Cancer: A Multicenter Phase II Study

Dendritic Cells Transduced with Full-Length Wild-Type p53 Generate Antitumor Cytotoxic T Lymphocytes from Peripheral Blood of Cancer Patients

Clinical Significance of Defective Dendritic Cell Differentiation in Cancer

Antibodies to Vascular Endothelial Growth Factor Enhance the Efficacy of Cancer Immunotherapy by Improving Endogenous Dendritic Cell Function

A Phase I Single-Dose Trial of Gadolinium Texaphyrin (Gd-Tex), a Tumor Selective Radiation Sensitizer Detectable by Magnetic Resonance Imaging

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only